DB05069InvestigationalSmall molecule
ATG003, a novel anti-angiogenic drug candidate and a formulation of mecamylamine, is currently in clinical development for neovascular age-related macular degeneration.
- Mechanism
- Curator reviewed
ATG003 acts by inhibiting the angiogenic pathway mediated by the nicotinic acetylcholine receptors found on endothelial cells (EC-NAChR). Inhibiting this pathway also inhibits the synthesis and cellular responses mediated by growth factors such as VEGF and bFGF.
- Primary indication
- Investigated for use/treatment in macular degeneration.Curator reviewed
- Code names
- ATG003
Resolves to
Targets
What you can answer from here — as of April 02, 2025
2Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with ATG003, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account